Wall Street’s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors…
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.
Arrowhead Pharmaceuticals Earns $50M Milestone From Royalty Pharma, Pursuant To Its 2016 Agreement With Amgen And 2022 Agreement With Royalty Pharma, Arrowhead Is Further Eligible To Receive Up To An Additional $375M From Amgen And $110M From Royalty P…
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ:RPRX). This milestone was triggered after the completion of enrollment of the
Looking Into Royalty Pharma’s Recent Short Interest
Royalty Pharma’s (NYSE:RPRX) short percent of float has fallen 3.91% since its last report. The company recently reported…
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell
• Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Royalty Pharma’s Earnings: A Preview
Royalty Pharma (NASDAQ:RPRX) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here’s what investors…
Watching MSCI Inc.; Spruce Point Capital Management Announces Investment Opinion Entitled “Indexing The Short Case Against MSCI”; Says The Co Could Face Up To 55%-65% Long-Term Downside Risk, Or $190.00–$244.00 Per Share
NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital ManagementProvides Evidence That Each of MSCI's Four Business Segments is Under Pressure, Resulting in Client Retention
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.